Developer docs
API playgroundTry for free, no card

Search company profiles

Engine Biosciences

Full company profile

uuid0000owl

Namestring
Engine Biosciences
Legal namestring
Engine Biosciences
Websiteurl
enginebio.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Engine Biosciences is a Singapore-headquartered biotechnology company that applies machine learning and computational biology to precision oncology drug discovery. Founded in 2016, the company operates dual hubs in Singapore (corporate headquarters) and Silicon Valley (US research and development and partnerships), with a team of 11-50 employees. Its core technology is the NetMappr platform, which maps biological network relationships to identify and validate therapeutic targets in cancer. Built on this platform, Engine Biosciences is developing a portfolio of precision oncology drug candidates targeting specific disease mechanisms, pursuing a platform-plus-pipeline business architecture.

The company pursues a partnership-led go-to-market focused on pharmaceutical and biotechnology firms developing cancer therapeutics, alongside academic and research institutions. Revenue is generated through drug discovery collaborations, licensing agreements, co-development arrangements, milestone payments, and royalties — commercial terms are negotiated on a partnership-by-partnership basis and are not publicly disclosed. Marketing channels include direct partner engagement, scientific conferences, and academic collaborations rather than direct product sales. The company is pre-commercial: it has no approved products on the market and is still advancing its pipeline.

Engine Biosciences has raised over $100 million cumulatively across multiple funding rounds since 2018, including a $43 million Series A in May 2021 led by Polaris Partners — at the time the largest biotech Series A in Singapore. Lead institutional backers include Polaris Partners, EDBI, 6 Dimensions Capital, DHVC, Baidu Ventures, Invus, and WuXi AppTec. In 2026, Engine Biosciences was reported to be among firms considering a listing on the Hong Kong Stock Exchange as part of the broader Asian IPO rebound.

Short descriptiontext

Engine Biosciences is a Singapore- and Silicon Valley-based biotech that uses its AI-powered NetMappr platform to map biological networks and develop precision oncology therapeutics for pharmaceutical partners and academic collaborators.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology therapeutics, computational drug discovery, AI genomics platform, biological network mapping, oncology drug development
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Precision Oncology Drug Discovery
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Development and Licensing
TypeLicensing Royalties
Description

Revenue generated through development of precision oncology therapeutics and licensing agreements with pharmaceutical partners. The company advances clinical programs and pursues collaborations in disease areas, potentially leading to milestone payments, royalties, and co-development arrangements.

finsmes.com
2Platform Technology Partnerships
TypeProfessional Services
Description

Partnerships leveraging the NetMappr platform for drug discovery collaborations with other biotechnology and pharmaceutical companies, generating revenue through research collaborations, service fees, and co-development agreements.

finsmes.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Engine Biosciences develops precision oncology therapeutics using its proprietary AI-powered NetMappr computational biology platform, which maps biological network relationships to identify and validate drug targets in cancer. The company operates a platform-plus-pipeline model, leveraging the NetMappr platform to discover targets and advance a portfolio of precision oncology drug candidates, while pursuing co-development and licensing agreements with pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Engine Biosciences operates as a precision oncology biotech company with a platform-plus-pipeline architecture. The core of their technology is the NetMappr computational biology platform, which maps biological network relationships to identify and validate drug targets. Built upon this platform, the company develops a portfolio of precision oncology therapeutics targeting specific disease mechanisms. The NetMappr platform serves as the foundational technology enabling the drug discovery and development programs.

Product and service2 records
1NetMappr Platform
CategoryDrug Discovery Platform
Description

AI-powered computational biology platform that maps biological network relationships to identify and validate therapeutic targets for precision oncology drug discovery. Used by pharmaceutical and biotechnology partners in research collaborations and co-development agreements.

2Precision Oncology Therapeutics Portfolio
CategoryOncology Therapeutics Pipeline
Description

A pipeline of precision oncology drug candidates developed internally using the NetMappr platform to target specific biological mechanisms in cancer. Licensed or co-developed with pharmaceutical partners under licensing, co-development, and milestone/royalty arrangements.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Engine Biosciences

Precision Oncology Drug Discoveryenginebio.com

Engine Biosciences is a Singapore- and Silicon Valley-based biotech that uses its AI-powered NetMappr platform to map biological networks and develop precision oncology therapeutics for pharmaceutical partners and academic collaborators.

What Engine Biosciences does

Engine Biosciences is a Singapore-headquartered biotechnology company that applies machine learning and computational biology to precision oncology drug discovery. Founded in 2016, the company operates dual hubs in Singapore (corporate headquarters) and Silicon Valley (US research and development and partnerships), with a team of 11-50 employees. Its core technology is the NetMappr platform, which maps biological network relationships to identify and validate therapeutic targets in cancer. Built on this platform, Engine Biosciences is developing a portfolio of precision oncology drug candidates targeting specific disease mechanisms, pursuing a platform-plus-pipeline business architecture.

The company pursues a partnership-led go-to-market focused on pharmaceutical and biotechnology firms developing cancer therapeutics, alongside academic and research institutions. Revenue is generated through drug discovery collaborations, licensing agreements, co-development arrangements, milestone payments, and royalties — commercial terms are negotiated on a partnership-by-partnership basis and are not publicly disclosed. Marketing channels include direct partner engagement, scientific conferences, and academic collaborations rather than direct product sales. The company is pre-commercial: it has no approved products on the market and is still advancing its pipeline.

Engine Biosciences has raised over $100 million cumulatively across multiple funding rounds since 2018, including a $43 million Series A in May 2021 led by Polaris Partners — at the time the largest biotech Series A in Singapore. Lead institutional backers include Polaris Partners, EDBI, 6 Dimensions Capital, DHVC, Baidu Ventures, Invus, and WuXi AppTec. In 2026, Engine Biosciences was reported to be among firms considering a listing on the Hong Kong Stock Exchange as part of the broader Asian IPO rebound.

Engine Biosciences firmographics

Firmographics
Name
Engine Biosciences
Legal name
Engine Biosciences
Website
https://enginebio.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Engine Biosciences is a Singapore- and Silicon Valley-based biotech that uses its AI-powered NetMappr platform to map biological networks and develop precision oncology therapeutics for pharmaceutical partners and academic collaborators.
Ownership category
akta.pro rank

Engine Biosciences industry classification

Industry
Product category
Precision Oncology Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Precision oncology therapeutics
  • Computational drug discovery
  • AI genomics platform
  • Biological network mapping
  • Oncology drug development

Where Engine Biosciences is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices3 records

Markets served

Engine Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. Drug Development and Licensing: Revenue generated through development of precision oncology therapeutics and licensing agreements with pharmaceutical partners. The company advances clinical programs and pursues collaborations in disease areas, potentially leading to milestone payments, royalties, and co-development arrangements.
  2. Platform Technology Partnerships: Partnerships leveraging the NetMappr platform for drug discovery collaborations with other biotechnology and pharmaceutical companies, generating revenue through research collaborations, service fees, and co-development agreements.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Engine Biosciences product offering

Product offering

Core offering

Engine Biosciences develops precision oncology therapeutics using its proprietary AI-powered NetMappr computational biology platform, which maps biological network relationships to identify and validate drug targets in cancer. The company operates a platform-plus-pipeline model, leveraging the NetMappr platform to discover targets and advance a portfolio of precision oncology drug candidates, while pursuing co-development and licensing agreements with pharmaceutical partners.

Product overview

Engine Biosciences operates as a precision oncology biotech company with a platform-plus-pipeline architecture. The core of their technology is the NetMappr computational biology platform, which maps biological network relationships to identify and validate drug targets. Built upon this platform, the company develops a portfolio of precision oncology therapeutics targeting specific disease mechanisms. The NetMappr platform serves as the foundational technology enabling the drug discovery and development programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • NetMappr Platform AI-powered computational biology platform that maps biological network relationships to identify and validate therapeutic targets for precision oncology drug discovery. Used by pharmaceutical and biotechnology partners in research collaborations and co-development agreements.
  • Precision Oncology Therapeutics Portfolio A pipeline of precision oncology drug candidates developed internally using the NetMappr platform to target specific biological mechanisms in cancer. Licensed or co-developed with pharmaceutical partners under licensing, co-development, and milestone/royalty arrangements.

Companies that use Engine Biosciences

Customer profile

Segments1 record

Ideal customer profiles1 record

Engine Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Engine Biosciences partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Engine Biosciences competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Engine Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Engine Biosciences leadership team

Management profile

Number of profiles

Profiles3 records

Engine Biosciences funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Engine Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Engine Biosciences

What does Engine Biosciences do?

Engine Biosciences develops precision oncology therapeutics using its proprietary AI-powered NetMappr computational biology platform, which maps biological network relationships to identify and validate drug targets in cancer. The company operates a platform-plus-pipeline model, leveraging the NetMappr platform to discover targets and advance a portfolio of precision oncology drug candidates, while pursuing co-development and licensing agreements with pharmaceutical partners.

Is Engine Biosciences a public or private company?

Engine Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Engine Biosciences founded?

Engine Biosciences was founded in 2016. It employs 11 to 50 people.

Where is Engine Biosciences based?

Engine Biosciences is headquartered in Singapore, Singapore, in the Asia region.

How does Engine Biosciences make money?

Two revenue lines are on record. Drug Development and Licensing is the primary driver. The others are platform Technology Partnerships.

Does Engine Biosciences have an API?

No public API is recorded for Engine Biosciences.

What industry is Engine Biosciences in?

Engine Biosciences's product category is Precision Oncology Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
DealStreetAsiaEditor's take: The week that was — Aug 10-15Startup fundraising in Southeast Asia and India experienced significant declines in July, while Greater China saw a surge driven by large transactions. The article also highlights specific corporate activities including Alphabet's GV investment in Engine Biosciences, GigaDevice Semiconductor's capital commitment to Yunfeng Capital, and Accel's fundraise for its India-focused vehicle.DealStreetAsiaPfizer Ventures makes first SE Asia startup investment in Engine BioPfizer Ventures made its first Southeast Asia startup investment in Engine Biosciences, a Singapore-based biotech. The company also recently opened a Silicon Valley office. No further details on the investment were disclosed.The Business TimesSingapore among global firms eyeing Hong Kong listings as IPO rebound broadensAbout 10 companies from Indonesia, South Korea and Singapore have filed for Hong Kong listings this year, with others exploring options, as the market's robust IPO momentum attracts global firms. Hong Kong, which was the world's top market for IPOs last year, is seeing its strongest year for international debuts since at least 2020, with a pipeline spanning technology, consumer and financials sectors. Swiss agrochemicals firm Syngenta Group plans a listing of up to US$10 billion in the second half of the year, while Singapore-based biotech Engine Biosciences and US-based NiKang Therapeutics are among firms considering possible listings.PR NewswireEngine Biosciences Appoints Renowned Drug Discovery and Development Leader Robert Abraham, PhD, as Chief Scientific OfficerEngine Biosciences announced the appointment of Robert Abraham, PhD, as Chief Scientific Officer, effective immediately. Dr. Abraham brings over three decades of experience in oncology drug discovery and development, having contributed to 11 FDA-approved oncology drugs during his career at companies including Pfizer, Vividion Therapeutics, and Odyssey Therapeutics. The appointment strengthens Engine's scientific and R&D leadership as the company advances its precision oncology pipeline toward clinical development.YahooEngine Biosciences and Experimental Drug Development Centre Partner to Advance Novel Therapies to Combat CancerEngine Biosciences and Singapore's Experimental Drug Development Centre announced a partnership to develop first-in-class precision cancer therapies. The first project targets ENB-871, a drug pairing for breast, liver, kidney, and prostate cancers, with a potential addressable population exceeding 500,000 patients per year.PR NewswireEngine Biosciences and Experimental Drug Development Centre Partner to Advance Novel Therapies to Combat CancerEngine Biosciences and Singapore's Experimental Drug Development Centre announced a partnership to develop first-in-class precision cancer therapies. The first project targets ENB-871, a drug pairing for breast, liver, kidney, and prostate cancers, addressing over 500,000 patients annually. The collaboration may expand to additional drug targets.TNGlobalFrom lab to cure: Three trailblazing trends for biotech startups in 2024APAC biotech startups face 2024 with three trends: strategic investments favoring quality, government support, and collaboration. Engine Biosciences raised $27M in a Series A extension, bringing total funds to $86M. Government programs and collaborative platforms are expected to boost the region's attractiveness to investors.Hive Life MagazineEngine Biosciences Raises US$27 Million to Advance Precision Oncology MedicineEngine Biosciences has closed a US$27 million Series A extension, bringing its total funding to US$86 million, with the round led by Polaris Partners. The company plans to use the capital to accelerate biomarker and target discovery for precision oncology medicines through internal development and strategic partnerships. New board member Wen Qi Ho from ClavystBio joins the leadership team as the startup expands its machine learning-driven drug discovery capabilities.TNGlobalSingapore's Engine Biosciences secures $27M in Series A extension led by Polaris PartnersEngine Biosciences, a Singapore-based precision oncology company, completed a $27 million Series A extension led by Polaris Partners. The financing brings total funds raised since inception to $86 million, with participation from existing and new investors. The company will use the funds to advance its biomarker and target discoveries toward the clinic.Business Wire BlogEngine Biosciences Secures $27 Million Series A Extension to Advance Development of Precision Oncology Medicines and Novel Biomarkers for Patient SelectionEngine Biosciences completed a $27 million Series A extension led by Polaris Partners, bringing total funds raised to $86 million. The financing will support clinical translation of its precision oncology medicines and biomarkers, including ENB-812.